ALX Oncology (ALXO) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nkarta (NKTX) has outperformed ALX Oncology (ALXO) over the past year, losing 4.7% versus a loss of 35.6%. Over five years, NKTX leads with a -87.7% price change compared with -97.9% for ALXO. ALX Oncology is the larger company by market cap ($172.8 million vs $161.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | NKTX |
|---|---|---|
| Share price | $1.25 | $2.25 |
| Market cap | $172.85M | $161.16M |
| 1-day change | +5.93% | +1.35% |
| YTD return | +10.62% | +21.62% |
| 1-year return | -35.57% | -4.66% |
| 5-year return | -97.88% | -87.73% |
| EPS (TTM) | $-1.20 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $3.72 |
| 52-week low | $1.05 | $1.70 |
| Distance from 52-week high | -53.01% | -39.52% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +268.00% | +381.33% |
| Average volume | 1.04M | 602.17K |
| Shares outstanding | 138.28M | 71.62M |
| Employees | 48 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NKTX has outperformed ALXO by 30.9 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
ALXO vs NKTX FAQ
Which is bigger, ALX Oncology or Nkarta?
ALX Oncology (ALXO) is larger, with a market capitalization of $172.85M compared with $161.16M for Nkarta (NKTX).
Which stock has performed better over the past year, ALXO or NKTX?
NKTX returned -4.66% over the past 12 months, compared with -35.57% for ALXO (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Nkarta in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.